Does the control of alanine aminotransferase levels lead to a regression of liver fibrosis in chronic hepatitis C patients?

Hepatology Research

Volumn 19, Issue 2, 2001, Pages 144-157

  Yagura, Michiyasu ^a   Murai, Seiyou ^a   Kojima, Hiroshi ^a   Tokita, Hajime ^a   Kamitsukasa, Hiroshi ^a   Harada, Hideharu ^a  

^a National Hospital Organization   (Japan)

Author keywords

Aminoterminal peptide of type III procollagen; Chronic hepatitis C; Liver fibrosis; Morphometric image analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BIOCHEMICAL MARKER; INTERFERON; LIVER ENZYME; NEOMINOPHAGEN C; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; URSODEOXYCHOLIC ACID; XIAO CHAI HU TANG; ZINC;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; THROMBOCYTE COUNT; TURBIDITY;

EID: 0035156416     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(00)00098-X     Document Type: Article

References (37)

1. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial
2. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double blind, placebo controlled trial
3. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis
4. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis
5. Classification of chronic hepatitis: Diagnosis, grading and staging
6. Radioimmunoassay for type III procollagen peptide and its application to human liver disease
7. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture
8. Interferon gamma decrease hepatic stellate cell activation and matrix deposition in rat liver fibrosis
9. Interferon γ but not α treatment prevents fibrosis by inhibiting procollagen and tissue inhibitor of metalloproteinase-1 gene expression in pig serum-induced rat liver fibrosis in vivo
10. The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis
11. Hepatoprotection by hydrophilic bile salts
12. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis
13. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: Possible role of bicarbonate transport
14. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
15. The effect of ursodeoxycholic acid in primary sclerosing cholangitis
16. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C
17. Treatment of hepatitis with the antiallergic drug, Stronger Neo-Minophagen C
18. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis
19. Clinical study of Shosaiko-to therapy to the Japanese patients with chronic hepatitis C (CH-C)
20. Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial
21. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients chronic active hepatitis. A 12-months double-blind, placebo-controlled trial
22. Effect of large dose of SNMC on the liver histology of chronic active hepatitis
23. Effect of Shosaiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats
24. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections
25. A simple estimation of liver collagen content by the computed color image analysis using sirius red stained sections
26. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle biopsy specimens: Comparison with morphometric studies
27. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies
28. α-Interferon in the treatment of chromic viral hepatitis: Effects on fibrogenesis serum markers
29. Serum type III procollagen N peptide (P III P) and laminin levels and hepatic immunohistochemical study in patients with various liver diseases
30. Do serum ALT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis?
31. Chronic hepatitis C: Clinicopathological correlation in 80 patients
32. Alanine aminotransferase measurements and histological disease in hepatitis C
33. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alaninetransaminase levels
34. Natural history of hepatitis C virus infected patients. Histological follow up of viremic subject with or without repeatedly normal amino transferase activity
35. Slow progression rate of fibrosis in hepatitis C patients with persistently normal alanine transaminase activity
36. Natural history of liver fibrosis progression in patients with chronic hepatitis C
37. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study